SEOM-GEICO Clinical Guidelines on cervical cancer (2023)
Clinical and Translational Oncology · 31.08.2024 · 26 (11) · 2771-2782
DOI: 10.1007/s12094-024-03604-3 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical and Translational Oncology, online erschienen am 31.08.2024. Verfasst von Luis Manso und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Univ. 12 de Octubre, Madrid, Spain. lmanso@salud.madrid.org. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries that have implemented human papillomavirus (HPV) vaccination and screening programs have seen dramatic reductions in CC incidence, while developing countries where these programs are not available continue to experience high rates of CC deaths. In early-stage CC, the primary treatment is surgery or radiotherapy, whereas concurrent chemo-radiotherapy (CRT) remains the conventional approach in locally advanced stages until the upcoming approval of immunotherapy. The incorporation of immunotherapy in combination with chemotherapy (with or without bevacizumab) in first line and as monotherapy in second line after platinum-based chemotherapy, has significantly increased overall survival (OS) in recurrent or metastatic CC. The purpose of this guideline is to summarize the most relevant evidence in the diagnosis, treatment, and follow-up of CC and to provide evidence-based recommendations for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital Univ. 12 de Octubre, Madrid, Spain. lmanso@salud.madrid.org.
- Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain.
- Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain.
- Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
- Medical Oncology Department, UGCI Oncol. Hosp Univer Regional y Virgen Victoria, IBIMA, Málaga, Spain.
- Medical Oncology Department, Instituto de Biomedicina de Sevilla (IBIS), University Hospital Virgen del Rocío, Seville, Spain.
Zitieren
APA
Manso, L., Ramchandani-Vaswani, A., Romero, I., Sánchez-Lorenzo, L., Bermejo-Pérez, M. J., Estévez-García, P., Fariña-Madrid, L., García García, Y., Gil-Martin, M., & Quindós, M. (2024). SEOM-GEICO Clinical Guidelines on cervical cancer (2023). Clinical and Translational Oncology, 26(11), 2771-2782. https://doi.org/10.1007/s12094-024-03604-3
Vancouver
Manso L, Ramchandani-Vaswani A, Romero I, Sánchez-Lorenzo L, Bermejo-Pérez MJ, Estévez-García P, et al. SEOM-GEICO Clinical Guidelines on cervical cancer (2023). Clinical and Translational Oncology. 2024;26(11):2771-2782. doi:10.1007/s12094-024-03604-3
BibTeX
@article{Manso2024,
author = {Manso, Luis and Ramchandani-Vaswani, Avinash and Romero, Ignacio and Sánchez-Lorenzo, Luisa and Bermejo-Pérez, María José and Estévez-García, Purificación and Fariña-Madrid, Lorena and García García, Yolanda and Gil-Martin, Marta and Quindós, María},
title = {SEOM-GEICO Clinical Guidelines on cervical cancer (2023)},
journal = {Clinical and Translational Oncology},
year = {2024},
volume = {26},
number = {11},
pages = {2771--2782},
doi = {10.1007/s12094-024-03604-3}
}
EUVIMED